- GlobeNewswire•2 days ago
PHILADELPHIA, Oct. 19, 2016-- Hemispherx Biopharma announced today that it has completed its technology transfer of the Ampligen ® manufacturing processes to Avrio Biopharmaceuticals. The transfer consists ...
- GlobeNewswire•29 days ago
PHILADELPHIA, Sept. 22, 2016-- Hemispherx Biopharma, announced today that the Court of Chancery of the State of Delaware has issued an order granting final approval of a settlement of the derivative and ...
- GlobeNewswire•last month
PHILADELPHIA, Sept. 19, 2016-- Hemispherx Biopharma, announced today that, based on a notice received on September 15, 2016 from the New York Stock Exchange, Inc., the Company has regained compliance with ...
Hemispherx Biopharma, Inc. (HEB)
NYSE MKT - NYSE MKT Real Time Price. Currency in USD
|Bid||1.05 x 1000|
|Ask||1.07 x 100|
|Day's Range||1.04 - 1.07|
|52wk Range||0.72 - 2.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.11|
|Avg Vol (3m)||163,109|
|Dividend & Yield||N/A (N/A)|